Gamida Cell Ltd. Files SEC Form S-3 Amidst Regulatory Filing Activity
U.S.-based publicly traded company Gamida Cell Ltd. has filed a new form with the Securities and Exchange Commission (SEC). According to the SEC filing, Gamida Cell Ltd. has submitted their Form S-3 on January 11, 2023, providing investors with critical information about the company's financials and operations. The filing is a significant step for Gamida Cell Ltd., enabling them to raise capital and make strategic decisions amidst regulatory requirements.
Key Takeaways:
- Gamida Cell Ltd. filed their SEC Form S-3 on January 11, 2023, which is the most simplified registration form required by the SEC.
- The company has been required to report under the '34 Act for a minimum of twelve months, meeting the timely filing requirements set forth under Form S-2.
- The offering and issuer meet the eligibility tests prescribed by Form S-3, allowing Gamida Cell Ltd. to incorporate by reference information from '34 Act filings.
- The SIC code for Gamida Cell Ltd. is 2836, Biological Products, (No Diagnostic Substances), and there were 6 documents filed with this form.
- The SEC file number associated with the filing is 0001213900-23-002257.
Statistics:
- The filing was made on January 11, 2023, as part of the company's ongoing commitment to regulatory compliance.
- The company's headquarters is located at 5 NAHUM HAFZADI STREET, JERUSALEM L3 95484, with a contact number of 97226595666.
- The filing marks the 6th document submitted under this form, providing comprehensive information about Gamida Cell Ltd.'s operations and financials.
- Gamida Cell Ltd. has successfully navigated the process of submitting a simplified registration with the SEC, aligning with the regulatory requirements specified under Form S-3.
Sources:
- NewsRx, Life Science Weekly, 2023 JAN 24, "Gamida Cell Ltd. Filing with SEC".
- U.S. Securities and Exchange Commission (SEC) filing by Gamida Cell Ltd., Form S-3, January 11, 2023, SEC file number 0001213900-23-002257.